Coronavirus: Pfizer says vaccine 95% effective in final analysis of clinical trial

Error. Something went wrong. How does the Pfizer vaccine work and when will it be available.

Drugmaker Pfizer said a final analysis has revealed that its COVID-19 vaccine was 95% effective in a clinical trial.

BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.

— Pfizer Inc. (@pfizer) November 18, 2020

The company, along with partner BioNTech, announced the update in a news release Wednesday.

“After conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints,” the release said. “Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from seven days after the second dose.”

In the trial, which enrolled more than 43,000 participants, researchers recorded 170 coronavirus cases, the companies said. Of those cases, 162 occurred among placebo recipients, while just eight occurred in those who received the vaccine, the news release said.

Additionally, efficacy was more than 94% for adults over age 65, the companies said. An independent Data Monitoring Committee also “has not reported any serious safety concerns related to the vaccine,” according to the release.

The companies said they will submit an application “within days” to the U.S. Food and Drug Administration for emergency use authorization.

The announcement came two days after biotech company Moderna said an early analysis found its COVID-19 vaccine candidate was 94.5% effective in a clinical trial, according to The Associated Press. Pfizer also announced on Nov. 9 that early data suggested its vaccine was more than 90% effective.

We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.

Read more:

— Moderna (@moderna_tx) November 16, 2020

UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.

— Pfizer Inc. (@pfizer) November 9, 2020

More coronavirus pandemic coverage:

© 2020 Cox Media Group

How COVID-19 Accelerated a New Frontier of Data Analytics and Business Intelligence

How COVID-19 Accelerated a New Frontier of Data Analytics and Business Intelligence. Photo credit to @max_776, Adobe stock. The year 2020 will …

The year 2020 will forever be known as the year of COVID-19. The virus disrupted people’s lives in ways never envisioned and also claimed over a million lives. But amidst this tragedy, one positive development is that the pandemic has forced individuals, corporations, and governments to become much more adept at analyzing data to make informed decisions.

Most individuals, if asked, could tell you how many new COVID-19 cases were confirmed in their city, province, state, or country in the past 24 hours. They could likely even compare a given day’s case count to that of the previous day and identify trends in the evolution of the virus, a process similar to what a data analyst would do when data mining.

Ultimately, people are looking at data and interpreting it to make decisions at an unprecedented rate

The main purpose of checking the number of cases in one’s region is to make informed decisions. If you see that COVID-19 cases are trending upwards, you might decide to cancel your weekend plans, or you might stock up on food as you anticipate another lockdown. On the other hand, if cases are going down, you may choose to gather with a few friends (with social distancing, of course). Ultimately, people are looking at data and interpreting it to make decisions at an unprecedented rate.

In the early days of the pandemic, McGill University launched a student-run initiative called COVID-QC, led by Professor Juan Serpa. COVID-QC provides approximate real-time information about case counts in different parts of Quebec, as well as graphs depicting the evolution of cases, deaths, and recovery numbers. Such an initiative not only shows that individuals have become more comfortable with manipulating and organizing data, but it also helps others make informed decisions by providing them with user-friendly dashboards.

Corporations have been forced to make huge adjustments to their operations, and while some companies like Amazon and Zoom have benefited from lockdowns, most businesses have found themselves in precarious situations. Just like individuals, companies have made extensive use of data since the start of the pandemic. According to a survey from Sisense, 50 percent of companies are using data analytics “more or much more” than before the pandemic, including over 68 percent of small businesses.

…companies that favour data-driven decision-making are more likely to successfully manage the crisis and to recover faster than businesses who do not make use of data analytics…

The survey found that business intelligence applications are often used in customer relationship management (CRM). For example, a major challenge of the COVID-19 pandemic is ensuring that clients feel safe when visiting brick-and-mortar stores. Thanks to business intelligence tools, CRM systems, and social networking platforms, companies can obtain direct feedback from their customers and put measures in place to guarantee the health and safety of everyone. Business intelligence tools, such as decision support systems (DSS), have also allowed companies to produce sales forecasts and stress-tests, which are especially useful for assessing a company’s ability to operate under challenging economic scenarios.

Using DSS, companies can perform sensitivity analyses to evaluate the impacts that external variables, such as a possible lockdown or employee sickness, have on their operations. A podcast by McKinsey & Company revealed the importance of financial stress-testing, or scenario-based forecasting, to provide “much-needed clarity” for businesses struggling to cope with the pandemic conditions. According to Deloitte, companies that favour data-driven decision-making are more likely to successfully manage the crisis and to recover faster than businesses who do not make use of data analytics, as data-driven organizations manage core business operations in the most cost-effective way.

Governments are also using data extensively as the crisis continues, providing daily updates to the public about the state of COVID-19. When governments make decisions regarding the implementation or removal of lockdown restrictions, they do so by analyzing data and measuring ratios such as the R-number (rate of spread) or the number of infections per one million inhabitants.

The most noticeable use of data by some governments is perhaps the development of contact tracing applications, which alert individuals when they are in proximity to someone who has tested positive for COVID-19. The government of Canada recently launched its own COVID-19 contact tracing app, COVID Alert, which has been downloaded over five million times so far across eight provinces. Other applications of data analytics in the context of the COVID-19 pandemic include technology companies assisting governments and corporations. An example is Salesforce, a cloud-based software company, which provides free tools to help emergency response teams, as well as safe return-to-work strategies for companies.

There is nothing like a pandemic to make us realize just how impactful data-based decision making is for everyone. In an increasingly complex decision-making environment, sophisticated tools and frameworks for decision making are crucial for individuals to make wise choices, for companies to perform in the marketplace, and for governments to be effective when delivering information and services to the public. We might never master the science of decision-making, but one thing is for certain: we are getting better at it.

Print Friendly, PDF & Email

Urgent Plama Donations Continue in South Korea as Global Covid-19 Cases Surge Once More

… of the Testimony (Shincheonji) announced they will be having a third round of convalescent plasma donations beginning on November 16th through …

Plasma donations will take place in the Daegu Athletics Promotion Center from November 16th to December 11th.

Four Thousand Cured Covid-19 Patients from the Shincheonji, Church of Jesus, Give their Plasma in a Third Round of Donations

NEW YORK, NY, USA, November 10, 2020 / — Shincheonji, the Church of Jesus, the Temple of the Tabernacle of the Testimony (Shincheonji) announced they will be having a third round of convalescent plasma donations beginning on November 16th through December 11th at the Daegu Athletics Promotion Center. Approximately 4,000 members who have fully recovered from Covid-19 plan to donate their plasma in hopes to help develop a viable treatment containing antibodies which may fight against COVID-19.

Last month, the Korea Centers for Disease Control and Prevention (KCDC) requested the cooperation of Shincheonji for more plasma donations. The KCDC stated, “With the continuous outbreak of COVID-19 domestically and internationally, with no effective treatments, it is necessary to develop a treatment system through group plasma donations.”

Previously, Shincheonji organized two group plasma donations. The first donation was in July and the second one was in September. Thus far, 2,030 people have donated and approximately 1,700 are members of Shincheonji. There are 312 people who have donated their plasma at least twice.

In a press briefing on November 3, Kwon Joon-Wook, the deputy director of the Central Anti-Disaster Headquarters, stated, “We are grateful for Shincheonji’s active participation and cooperation with the Daegu Metropolitan City and the Korean Red Cross.”

An official of the Shincheonji stated, “I was happy and grateful to hear on the news that the blood plasma was being used on the medical site. This is the most valuable thing we can do. “He also added, “Through the experience of plasma donations, the members realize the power to overcome COVID-19 is built on love and unity. We will do our best to help the Republic of Korea overcome COVID-19.”

The official added, “We understand that there are voices of concern as church facilities are ordered to be closed down by region. Everyone may rest assured as Shincheonji, Church of Jesus, will maintain its online service until COVID-19 is stabilized. Our facilities will remain closed for the protection of our members and the health and safety of the community.”

Amanda Askew

Shincheonji Church

+1 646-504-4023

email us here

You just read:

News Provided By
November 10, 2020, 23:35 GMT
Share This Article

EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™, tries to define some of the boundaries that are reasonable in today’s world. Please see our Editorial Guidelines for more information.

Submit your press release

Remdesivir Market 2020 Size, Growth Share & Trends Analysis, Technological Advancements …

Global Remdesivir Market report focusing on enterprise Size, infrastructure investment analysis, market trends and development, drivers of the …


“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Report Title: “Global Remdesivir Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery”.

Global Remdesivir Market report focusing on enterprise Size, infrastructure investment analysis, market trends and development, drivers of the industry. The report study provides product demand status across different regions, size & share, market revenue analysis, import-export details, and production capacity. The scope of the Remdesivir market report includes a comprehensive study of global, regional, and local markets for different segments of the market.

Get a Sample Copy of the Report at –

Key Players Covered in the Global Remdesivir Market Are:

  • Gilead Sciences
  • Hunan Warrant Pharmaceutical
  • Bright Gene
  • Hainan Haiyao
  • Kelun Pharma
  • Remdesivir Market Segments by Types:

  • 10 mM*1 mL in DMSO
  • 5mg
  • 10mg
  • 50mg
  • 100mg
  • Remdesivir Market Segments by Applications:

  • Hospital
  • Clinics
  • Drug Store
  • Others
  • To Understand How Covid-19 Impact Is Covered in This Report –

    Scope of Remdesivir Market Report:

    Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status, enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analysed scientifically, the trends of product circulation and sales channel will be presented as well.

    • This report provides an analysis of the impact of COVID-19 on the global economy and the Remdesivir industry.
    • Remdesivir market report covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
    • In addition, consider the impact of COVID-19 on the regional economy.

    Years considered for this report:

    • Historical Years: 2015-2019
    • Base Year: 2019
    • Estimated Year: 2020
    • Forecast Period: 2020-2025

    Inquire or Share Your Questions If Any Before the Purchasing This Report –

    Regional Segmentation:

    • North America Country (United States, Canada)
    • South America
    • Asia Country (China, Japan, India, Korea)
    • Europe Country (Germany, UK, France, Italy)
    • Other Country (Middle East, Africa, GCC)

    Reason to buy Remdesivir Market Report:

    • In-depth analysis of the market at the global and regional level.
    • Major changes in market dynamics and competitive landscape.
    • Segmentation based on type, application, geography and other.
    • Historical and future market research in terms of size, share, growth, volume and aspect; sales.
    • Major changes in market dynamics and valuation development.
    • Industrial scale & Share industry growth and trends and analysis.
    • Key emerging sectors and regions
    • Key business strategies by key market players and key methods.
    • The research report covers the size, share, trends and growth analysis of the Remdesivir market at the global and regional level.

    Purchase this Report (Price 3500 USD for a Single-User License) –

    Detailed TOC of Remdesivir Market Forecast Report 2020-2025:

    1 Remdesivir Market Overview

    1.1 Objectives of Study

    1.2 Overview of Remdesivir

    1.3 Scope of Study

    1.3.1 Key Market Segments

    1.3.2 Players Covered

    1.3.3 COVID-19 Impact on the Remdesivir Industry

    1.4 Methodology of the Study

    1.5 Research Data Source

    2 Executive Summary

    2.1 Market Overview

    2.1.1 Global Remdesivir Market Size, 2015 – 2020

    2.1.2 Global Remdesivir Market Size by Type, 2015 – 2020

    2.1.3 Global Remdesivir Market Size by Application, 2015 – 2020

    2.1.4 Global Remdesivir Market Size by Region, 2015 – 2025

    2.2 Business Environment Analysis

    2.2.1 Global COVID-19 Status and Economic Overview

    2.2.2 Influence of COVID-19 Outbreak on Remdesivir Industry Development

    3 Industry Chain Analysis

    3.1 Upstream Raw Material Suppliers of Remdesivir Analysis

    3.2 Major Players of Remdesivir

    3.3 Remdesivir Manufacturing Cost Structure Analysis

    3.3.1 Production Process Analysis

    3.3.2 Manufacturing Cost Structure of Remdesivir

    3.3.3 Labor Cost of Remdesivir

    3.4 Market Distributors of Remdesivir

    3.5 Major Downstream Buyers of Remdesivir Analysis

    3.6 The Impact of Covid-19 From the Perspective of Industry Chain

    3.7 Regional Import and Export Controls Will Exist for a Long Time

    3.8 Continued downward PMI Spreads Globally

    4 Global Remdesivir Market, by Type

    5 Remdesivir Market, by Application

    6 Global Remdesivir Market Analysis by Regions

    For Detailed TOC –

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Dissolving Wood Pulp (DWP) Market Size 2020 – Business Share, Economic Impact of Key Players, Growth Investigation with Revenue, COVID-19 Impact, Opportunities and Regional Forecast to 2026

    Inkjet Film Market 2020: COVID-19 Impact on Industry Size and Share, Business Challenges, Future Growth and Revenue Expectations Forecast to 2025 | Report by Industry

    Industrial Inclination Sensors Market Share 2020 by Top Key Players Profiles with COVID-19 Analysis, Regional Opportunities, Organization Size, Recent Demand Trends, Business Strategies Forecast to 2026

    Cryogenic Insulation Films Market Size with Growth Status 2020 | Share and Gross Margin Analysis with COVID-19 Impact, Top Companies, Revenue, Business Development Plans Forecast to 2026

    Peptide Synthesizer Market Size 2020 | Explosive Growth Opportunities, Top Key Players with Revenue, Emerging Trends with Share Analysis Forecast to 2025 Report by Industry

    Meloxicam Market by Growth Size Analysis 2020 | Future Trends by Regions, Prominent Players, Global Developments Status, Industry Segments with Business Share Forecast to 2026

    NDIR CO2 Sensor Market 2020 with Global Industry Size and Share, Future Growth Rate, Leading Players Analysis, Trending Technologies, Business Strategies Forecast to 2026

    Airbag Textile Market Share, Growth Analysis 2020 – Industry Size with Regional Segmentations, Business Challenges and Opportunities Forecast to 2024

    Incubator Shaker Market by Major Drivers 2020 – Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Value and Forecasts till 2026

    Automotive Power Modules Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025

    V2X Market for Automotive Market Share 2020: Global Industry Outlook by Growth Segments, Types, Applications, and End-User Analysis Industry Size, Forecast to 2026

    Self-Balancing Electric Vehicles Market Share 2020: Global Industry Outlook by Growth Segments, Types, Applications, and End-User Analysis Industry Size, Forecast to 2026

    Study finds Hydroxychloroquine does not help patients hospitalized with COVID-19

    As lead investigator of the national Hydroxychloroquine study, he explained, “There was really good reason to believe Hydroxychlorquine could have …

    NASHVILLE, Tenn. (WKRN) — Hydroxychloroquine became a very commonly used medication for COVID-19 in the spring without strong evidence that it would be beneficial, explained Dr. Wesley Self, Vice President of Clinical Research at Vanderbilt University Medical Center.

    “When the COVID pandemic hit we were scrambling, as the whole world was, for the best way to treat patients. The first thing to do is really look at all the medication you already have access to,” said Dr. Self.

    As lead investigator of the national Hydroxychloroquine study, he explained, “There was really good reason to believe Hydroxychlorquine could have been helpful. We know it decreases what we call systemic inflammation and that’s a big part of COVID-19.”

    Thirty-four hospitals across the United States participated in the clinical trial.

    “We studied 479 patients. Half of them had Hydroxychloroquine and half were given a placebo which basically has nothing in it. All of those patients had COVID-19. All were quite sick,” said Dr. Self.

    The findings published today in the Journal of the American Medical Association found patients had the same clinical outcomes.

    “The same number died, which is about ten percent, unfortunately, in both groups,” said Dr. Self. “It took the same length of time to recover and the same amount of oxygen was necessary in both groups.”

    While Dr. Self says this news is disappointing, the team has shifted its focus to investigating the potential benefits of other treatments.

    Stay with News 2 for continuing coverage of the COVID-19 Pandemic.


    COVID-19 in Tennessee

    (This reflects what the TDH is reporting each day at 2 p.m. CST )